KEAP1 and neoplasm: Aberrant activation of NRF2 via KEAP1 mutation is also associated with poor clinicopathological outcomes, including low-response rate to platinum-based chemotherapy, increased metastasis (long distance, lymph node, and tumor node), poor overall survival rate, and poor progression-free survival (33, 34).